STAAR Surgical (STAA) 10-Q6 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 29, 2023	Oct. 27, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 29, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Registrant Name	STAAR Surgical Company
Entity Central Index Key	0000718937
Current Fiscal Year End Date	--12-29
Entity Filer Category	Large Accelerated Filer
Trading Symbol	STAA
Entity Common Stock, Shares Outstanding		48,817,473
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	0-11634
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Tax Identification Number	95-3797439
Entity Address, Address Line One	25651 Atlantic Ocean Drive
Entity Address, City or Town	Lake Forest
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92630
City Area Code	626
Local Phone Number	303-7902
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Current assets:
Cash and cash equivalents	$ 127,432	$ 86,480
Investments available for sale	60,681	125,159
Accounts receivable trade, net of allowance for credit losses of $38 and $20, respectively	112,367	62,447
Inventories, net	31,061	24,161
Prepayments, deposits and other current assets	15,527	13,476
Total current assets	347,068	311,723
Investments available for sale	13,627	13,902
Property, plant and equipment, net	62,886	50,921
Finance lease right-of-use assets, net	220	342
Operating lease right-of-use assets, net	34,992	30,270
Intangible assets, net		173
Goodwill	1,786	1,786
Deferred income taxes	8,560	8,744
Other assets	2,382	957
Total assets	471,521	418,818
Current liabilities:
Accounts payable	8,786	11,576
Obligations under finance leases	164	169
Obligations under operating leases	4,003	3,524
Allowance for sales returns	7,557	5,706
Other current liabilities	36,265	30,741
Total current liabilities	56,775	51,716
Obligations under finance leases	84	210
Obligations under operating leases	31,643	27,136
Deferred income taxes	1,295	1,489
Asset retirement obligations	98	220
Pension liability	3,031	1,935
Total liabilities	92,926	82,706
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 60,000 shares authorized: 48,817 and 48,212 shares issued and outstanding at September 29, 2023 and December 30, 2022, respectively	488	482
Additional paid-in capital	436,117	404,189
Accumulated other comprehensive gain (loss)	(2,886)	156
Accumulated deficit	(55,124)	(68,715)
Total stockholders’ equity	378,595	336,112
Total liabilities and stockholders’ equity	$ 471,521	$ 418,818

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses, current	$ 38	$ 20
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	48,817,000	48,212,000
Common stock, shares outstanding	48,817,000	48,212,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 80,308	$ 76,046	$ 246,142	$ 220,347
Cost of sales	16,670	15,584	54,216	46,749
Gross profit	63,638	60,462	191,926	173,598
Selling, general and administrative expenses:
General and administrative	19,266	14,011	55,461	39,934
Selling and marketing	26,607	23,130	85,238	64,633
Research and development	11,470	9,616	33,535	26,193
Total selling, general and administrative expenses	57,343	46,757	174,234	130,760
Operating income	6,295	13,705	17,692	42,838
Other income (expense), net:
Interest income, net	1,690	897	5,287	934
Loss on foreign currency transactions	(1,384)	(2,129)	(3,240)	(4,904)
Royalty income	74	77	74	527
Other income, net	71	27	144	178
Total other income (expense), net	451	(1,128)	2,265	(3,265)
Income before income taxes	6,746	12,577	19,957	39,573
Provision for income taxes	1,929	2,315	6,366	6,671
Net income	$ 4,817	$ 10,262	$ 13,591	$ 32,902
Net income per share:
Basic	$ 0.1	$ 0.21	$ 0.28	$ 0.69
Diluted	$ 0.1	$ 0.21	$ 0.27	$ 0.67
Weighted average shares outstanding:
Basic	48,613	48,102	48,426	47,915
Diluted	49,370	49,549	49,494	49,371

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ 4,817	$ 10,262	$ 13,591	$ 32,902
Defined benefit plans:
Net change in plan assets	(115)	465	(1,839)	7,126
Reclassification into other income (expense), net	(51)	54	(154)	139
Investments available for sale:
Change in unrealized gain (loss)	149	(432)	123	(432)
Reclassification into other income (expense), net			(2)
Foreign currency translation gain (loss)	(494)	(958)	(1,965)	(3,474)
Tax effect	146	312	795	379
Other comprehensive income (loss), net of tax	(365)	(559)	(3,042)	3,738
Comprehensive income	$ 4,452	$ 9,703	$ 10,549	$ 36,640

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2021	$ 261,568	$ 477	$ 373,519	$ (4,048)	$ (108,380)
Balance (in shares) at Dec. 31, 2021		47,716
Net Income (Loss)	32,902				32,902
Other comprehensive income (loss)	3,738			3,738
Common stock issued upon exercise of options	8,179	$ 4	8,175
Common stock issued upon exercise of options (in shares)		417
Stock-based compensation	$ 16,754		16,754
Unvested restricted stock (in shares)	4	7
Vested restricted and performance stock	$ 1	$ 1
Vested restricted and performance stock (in shares)		62
Balance at Sep. 30, 2022	323,142	$ 482	398,448	(310)	(75,478)
Balance (in shares) at Sep. 30, 2022		48,202
Balance at Jul. 01, 2022	302,317	$ 480	387,328	249	(85,740)
Balance (in shares) at Jul. 01, 2022		48,024
Net Income (Loss)	10,262				10,262
Other comprehensive income (loss)	(559)			(559)
Common stock issued upon exercise of options	5,034	$ 2	5,032
Common stock issued upon exercise of options (in shares)		166
Stock-based compensation	$ 6,088		6,088
Unvested restricted stock (in shares)	4
Vested restricted and performance stock (in shares)		12
Balance at Sep. 30, 2022	$ 323,142	$ 482	398,448	(310)	(75,478)
Balance (in shares) at Sep. 30, 2022		48,202
Balance at Dec. 30, 2022	336,112	$ 482	404,189	156	(68,715)
Balance (in shares) at Dec. 30, 2022		48,212
Net Income (Loss)	13,591				13,591
Other comprehensive income (loss)	(3,042)			(3,042)
Common stock issued upon exercise of options	$ 9,264	$ 5	9,259
Common stock issued upon exercise of options (in shares)	500	500
Stock-based compensation	$ 24,765		24,765
Repurchase of employee common stock for taxes withheld	$ (2,096)		(2,096)
Repurchase of employee common stock for taxes withheld (in shares)		(35)
Unvested restricted stock (in shares)	12	10
Vested restricted and performance stock	$ 1	$ 1
Vested restricted and performance stock (in shares)		130
Balance at Sep. 29, 2023	378,595	$ 488	436,117	(2,886)	(55,124)
Balance (in shares) at Sep. 29, 2023		48,817
Balance at Jun. 30, 2023	357,617	$ 485	419,594	(2,521)	(59,941)
Balance (in shares) at Jun. 30, 2023		48,499
Net Income (Loss)	4,817				4,817
Other comprehensive income (loss)	(365)			(365)
Common stock issued upon exercise of options	7,258	$ 3	7,255
Common stock issued upon exercise of options (in shares)		305
Stock-based compensation	9,380		9,380
Repurchase of employee common stock for taxes withheld	$ (112)		(112)
Repurchase of employee common stock for taxes withheld (in shares)		(1)
Unvested restricted stock (in shares)	12
Vested restricted and performance stock (in shares)		14
Balance at Sep. 29, 2023	$ 378,595	$ 488	$ 436,117	$ (2,886)	$ (55,124)
Balance (in shares) at Sep. 29, 2023		48,817

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 4,817	$ 10,262	$ 13,591	$ 32,902	$ 39,665
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation of property, plant, and equipment			3,743	3,101
Amortization/Impairment of intangibles			169	22
Accretion/Amortization of investments available for sale			(2,172)	(307)
Deferred income taxes			65	23	(2,254)
Change in net pension liability			(766)	40
Loss on disposal of property and equipment			41
Stock-based compensation expense			23,334	15,375
Change in asset retirement obligation			(104)
Provision for sales returns and bad debts			1,925	361
Inventory provision			4,090	2,020
Changes in working capital:
Accounts receivable			(50,436)	(13,108)
Inventories			(9,975)	(4,123)
Prepayments, deposits, and other current assets			(3,584)	526
Accounts payable			(3,266)	(1,834)
Other current liabilities			5,970	(2,253)
Net cash provided by (used in) operating activities			(17,375)	32,745
Cash flows from investing activities:
Acquisition of property and equipment			(15,100)	(14,083)
Purchase of investments available for sale			(52,314)	(95,576)
Proceeds from sale or maturity of investments available for sale			119,359
Net cash provided by (used in) investing activities			51,945	(109,659)
Cash flows from financing activities:
Repayment of finance lease obligations	(39)	(40)	(121)	(85)
Repurchase of employee common stock for taxes withheld			(2,096)
Proceeds from the exercise of stock options			9,264	8,179
Proceeds from vested restricted stock			1	1
Net cash provided by financing activities			7,048	8,095
Effect of exchange rate changes on cash and cash equivalents			(666)	(1,645)
Increase (decrease) in cash and cash equivalents			40,952	(70,464)
Cash and cash equivalents, at beginning of the period			86,480	199,706
Cash and cash equivalents, at end of the period	$ 127,432	$ 129,242	$ 127,432	$ 129,242	$ 86,480

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022	Dec. 30, 2021
Pay vs Performance Disclosure
Net Income (Loss)	$ 4,817	$ 10,262	$ 13,591	$ 32,902	$ 39,665	$ 27,511

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
Insider Trading Arrangements	Sep. 29, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
Basis of Presentation and Significant Accounting Policies	Sep. 29, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 — Basis of Presentation and Significant Accounting Policies The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of December 30, 2022 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022. The Condensed Consolidated Financial Statements for the three and nine months ended September 29, 2023 and September 30, 2022, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and nine months ended September 29, 2023 and September 30, 2022, are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks. Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries. Revision of Financial Statements for Correction of Immaterial Misstatements Subsequent to the issuance of the Company’s consolidated financial statements for the year ended December 30, 2022, the Company determined that it had not correctly deducted compensation expense in calculating its income tax provision, deferred tax asset and valuation allowance under the Incremental Cash Tax Method. This resulted in an understatement of the net deferred tax asset, an overstatement in the valuation allowance, an overstatement of the provision for income taxes and understatement of net income. In accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality, and SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated the error and determined that the related impact was not material to results of operations or financial position for any prior annual or interim period, but that correcting the cumulative impact of the error would be material to our results of operations for the year ended December 29, 2023. Accordingly, the Company has corrected the consolidated balance sheet as of December 30, 2022 and the consolidated statements of income and comprehensive income for the years ended December 30, 2022 and December 31, 2021. The effects of the revision on the previously issued consolidated financial statements were as follows: Condensed Consolidated Balance Sheet (in thousands) (Unaudited) December 30, 2022 As Previously Reported Adjustment As revised Deferred income taxes $ 4,824 $ 3,920 $ 8,744 Total assets 414,898 3,920 418,818 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Total liabilities and stockholders’ equity 414,898 3,920 418,818 Note 1 — Basis of Presentation and Significant Accounting Policies (Continued) Revision of Financial Statements for Correction of Immaterial Misstatements (Continued) Condensed Consolidated Statements of Stockholders’ Equity (in thousands) (Unaudited) As Previously Reported Adjustment As revised At December 31, 2021 Accumulated deficit $ ( 111,390 ) $ 3,010 $ ( 108,380 ) Total stockholders’ equity 258,558 3,010 261,568 At December 30, 2022 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Condensed Consolidated Statements of Income and Comprehensive Income (in thousands, except per share amounts) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Provision (benefit) for income taxes $ 6,797 $ ( 910 ) $ 5,887 $ 6,803 $ ( 3,010 ) $ 3,793 Net income 38,755 910 39,665 24,501 3,010 27,511 Comprehensive income 42,959 910 43,869 25,998 3,010 29,008 Net income per share: Basic $ 0.81 $ 0.02 $ 0.83 $ 0.52 $ 0.06 $ 0.58 Diluted $ 0.78 $ 0.02 $ 0.80 $ 0.50 $ 0.06 $ 0.56 Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Cash flows from operating activities Net income $ 38,755 $ 910 $ 39,665 $ 24,501 $ 3,010 $ 27,511 Deferred income taxes ( 1,344 ) ( 910 ) ( 2,254 ) 1,495 ( 3,010 ) ( 1,515 ) Note 1 — Basis of Presentation and Significant Accounting Policies (Continued) Cloud-Based Software Implementation Costs The Company has entered into cloud-based software hosting arrangements for which it incurs implementation costs. Certain costs incurred during the application development stage are capitalized and included within Prepayments, deposits and other current assets or Other assets on the condensed consolidated balance sheet, depending on the short or long-term nature of such costs, in line with the Company's policy on the accounting for prepaid software hosting arrangements. Costs incurred during the preliminary project stage and post-implementation stage are expensed as incurred. Capitalized cloud-based software implementation costs are amortized, beginning on the date the related software or module is ready for its intended use, on a straight-line basis over the remaining term of the hosting arrangement. Amortization is recognized as a component of selling, general, and administrative expenses, in the same line item as the expense for the associated hosting arrangement. As of September 29, 2023 , the Company recognized $ 1,318,000 of net capitalized cloud-based software implementation costs recorded within Other assets on the condensed consolidated balance sheets. There were no capitalized cloud-based software implementation costs recognized at December 30, 2022. As of September 29, 2023 , these assets are not currently placed into service. No amortization of capitalized cloud-based software implementation costs were recognized during the three and nine months ended September 29, 2023 .

Investments Available for Sale

Investments Available for Sale	9 Months Ended
Investments Available for Sale	Sep. 29, 2023
Investments, Debt and Equity Securities [Abstract]
Investments Available for Sale	Note 2 — Investments Available for Sale During the second half of 2022, the Company started to invest its cash in slightly higher yielding securities. Investments available for sale (“AFS”) and the related fair value measurement consisted of the following (dollars in thousands): September 29, 2023 Fair Value Measurements Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Level 1 Level 2 Commercial paper $ 17,102 $ 1 $ ( 5 ) $ 17,098 $ — $ 17,098 Certificates of deposit 4,080 1 ( 2 ) 4,079 — 4,079 U.S. Treasury securities 24,828 — ( 188 ) 24,640 24,640 — U.S. agency securities 9,771 — ( 21 ) 9,750 — 9,750 Corporate debt securities 18,812 2 ( 73 ) 18,741 — 18,741 Total investments AFS $ 74,593 $ 4 $ ( 289 ) $ 74,308 $ 24,640 $ 49,668 December 30, 2022 Fair Value Measurements Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Level 1 Level 2 Commercial paper $ 44,054 $ 11 $ ( 62 ) $ 44,003 $ — $ 44,003 Certificates of deposit 17,355 4 ( 75 ) 17,284 — 17,284 U.S. Treasury securities 21,847 3 ( 15 ) 21,835 21,835 — U.S. agency securities 10,688 16 ( 3 ) 10,701 — 10,701 Corporate debt securities 45,522 4 ( 288 ) 45,238 — 45,238 Total investments AFS $ 139,466 $ 38 $ ( 443 ) $ 139,061 $ 21,835 $ 117,226 The Company obtains the fair value from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. Note 2 — Investments Available for Sale (Continued) The Company assessed each debt security with gross unrealized losses for impairment. As part of that assessment, the Company concluded that it does not intend to sell and it is more-likely-than-not that the Company will not be required to sell, prior to the recovery of the amortized cost basis. The Company did no t recognize impairment for the three and nine months ended September 29, 2023. The following table shows the fair value of investments AFS by contractual maturity (dollars in thousands): As of September 29, 2023 Within one year After one year through five years Total Commercial paper $ 17,098 $ — $ 17,098 Certificates of deposit 4,079 — 4,079 U.S. Treasury securities 14,855 9,785 24,640 U.S. agency securities 9,354 396 9,750 Corporate debt securities 15,295 3,446 18,741 Total investments AFS $ 60,681 $ 13,627 $ 74,308 During the nine months ended September 29, 2023 , the Company sold $ 600,000 in securities during the first quarter of 2023 due to a downgraded credit rating. The Company recognized a realized gain upon sale of $ 2,000 during the nine months ended September 29, 2023 .

Inventories

Inventories	9 Months Ended
Inventories	Sep. 29, 2023
Inventory Disclosure [Abstract]
Inventories	Note 3 — Inventories Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands): September 29, 2023 December 30, 2022 Raw materials and purchased parts $ 9,591 $ 6,703 Work in process 6,451 5,499 Finished goods 18,944 13,633 Total inventories, gross 34,986 25,835 Less inventory reserves ( 3,925 ) ( 1,674 ) Total inventories, net $ 31,061 $ 24,161

Prepayments, Deposits, and Othe

Prepayments, Deposits, and Other Current Assets	9 Months Ended
Prepayments, Deposits, and Other Current Assets	Sep. 29, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepayments, Deposits, and Other Current Assets	Note 4 — Prepayments, Deposits, and Other Current Assets Prepayments, deposits, and other current assets consisted of the following (in thousands): September 29, 2023 December 30, 2022 Prepayments and deposits $ 5,830 $ 3,986 Prepaid insurance 455 2,620 Prepaid marketing costs 4,543 2,534 Consumption tax receivable 777 864 Value added tax (VAT) receivable 2,189 2,661 BVG (Swiss Pension) prepayment 801 111 Other (1) 932 700 Total prepayments, deposits and other current assets $ 15,527 $ 13,476 (1) No individual category in “other current assets” exceeds 5 % of the total prepayments, deposits and other current assets.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
Property, Plant and Equipment	Sep. 29, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 5 — Property, Plant and Equipment Property, plant and equipment, net consisted of the following (in thousands): September 29, 2023 December 30, 2022 Machinery and equipment $ 29,461 $ 28,026 Computer equipment and software 8,329 9,266 Furniture and fixtures 4,110 4,276 Leasehold improvements 10,047 14,965 Construction in process 40,174 32,269 Total property, plant and equipment, gross 92,121 88,802 Less accumulated depreciation ( 29,235 ) ( 37,881 ) Total property, plant and equipment, net $ 62,886 $ 50,921

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6 – Intangible Assets Intangible assets, net consisted of the following (in thousands): September 29, 2023 December 30, 2022 Long-lived amortized intangible assets Gross Accumulated Net Gross Accumulated Net Patents and licenses $ 9,180 $ ( 9,180 ) $ — $ 9,240 $ ( 9,067 ) $ 173 During the nine months ended September 29, 2023 , the Company recognized full impairment of $ 154,000 for its Japan patents and licenses related to cataract IOLs.

Other Current Liabilities

Other Current Liabilities	9 Months Ended
Other Current Liabilities	Sep. 29, 2023
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Note 7 – Other Current Liabilities Other current liabilities consisted of the following (in thousands): September 29, 2023 December 30, 2022 Accrued salaries and wages $ 11,813 $ 10,862 Accrued bonuses 2,517 6,925 Income taxes payable 8,540 3,845 Marketing obligations 1,571 1,374 Other (1) 11,824 7,735 Total other current liabilities $ 36,265 $ 30,741 (1) No individual category in “Other” exceeds 5 % of the other current liabilities.

Leases

Leases	9 Months Ended
Leases	Sep. 29, 2023
Leases [Abstract]
Leases	Note 8 – Leases Finance Leases The Company entered into finance leases primarily related to purchases of equipment used for manufacturing, computer-related equipment or furniture and fixtures. These finance leases are two to five years in length and have fixed payment amounts for the term of the contract and have options to purchase the assets at the end of the lease term. Supplemental balance sheet information related to finance leases consisted of the following (dollars in thousands): Note 8 – Leases (Continued) Finance Leases (Continued) September 29, 2023 December 30, 2022 Machinery and equipment $ — $ 30 Computer equipment and software 6 18 Furniture and fixtures 475 475 Finance lease right-of-use assets, gross 481 523 Less accumulated depreciation ( 261 ) ( 181 ) Finance lease right-of-use assets, net $ 220 $ 342 Current finance lease obligations $ 164 $ 169 Long-term finance lease obligations 84 210 Total finance lease liability $ 248 $ 379 Weighted-average remaining lease term (in years) 1.5 2.2 Weighted-average discount rate 4.23 % 4.10 % Supplemental cash flow information related to finance leases consisted of the following (dollars in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Amortization of finance lease right-of-use asset $ 37 $ 39 $ 114 $ 121 Interest on finance lease liabilities 3 5 10 13 Cash paid for amounts included in the measurement of finance lease liabilities: Operating cash flows 3 5 10 13 Financing cash flows 39 40 121 85 Operating Leases The Company entered into operating leases primarily related to real property (office, manufacturing and warehouse facilities), automobiles and copiers. These operating leases are two to ten years in length with options to extend. The Company does not include any lease extensions in the initial valuation unless the Company was reasonably certain to extend the lease. Depending on the lease, there are those with fixed payment amounts for the entire length of the contract or payments which increase periodically as noted in the contract or increased at an inflation rate indicator. For operating leases that increase using an inflation rate indicator, the Company used the inflation rate at the time the lease was entered into for the length of the lease term. Supplemental balance sheet information related to operating leases consisted of the following (dollars in thousands): September 29, 2023 December 30, 2022 Machinery and equipment $ 726 $ 789 Computer equipment and software 446 446 Real property 41,313 34,465 Operating lease right-of-use assets, gross 42,485 35,700 Less accumulated depreciation ( 7,493 ) ( 5,430 ) Operating lease right-of-use assets, net $ 34,992 $ 30,270 Current operating lease obligations $ 4,003 $ 3,524 Long-term operating lease obligations 31,643 27,136 Total operating lease liability $ 35,646 $ 30,660 Weighted-average remaining lease term (in years) 7.5 7.5 Weighted-average discount rate 5.15 % 3.87 % Note 8 – Leases (Continued) Operating Leases (Continued) Supplemental cash flow information related to operating leases was as follows (dollars in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Operating lease cost $ 1,419 $ 1,167 $ 3,883 $ 3,471 Cash paid for amounts included in the measurement of operating lease liabilities: Operating cash flows 1,259 1,103 3,584 3,069 Right-of-use assets obtained in exchange for new operating lease liabilities 4,580 126 8,000 1,166 Future Maturities of Lease Liabilities Estimated future maturities of lease liabilities under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of September 29, 2023 is as follows (in thousands): . As of September 29, 2023 Operating Leases Finance Leases September 2024 $ 5,957 $ 171 September 2025 5,630 85 September 2026 4,987 — September 2027 5,319 — September 2028 5,381 — Thereafter 18,105 — Total future minimum lease payments $ 45,379 $ 256 Less amounts representing interest ( 9,733 ) ( 8 ) Total lease liability $ 35,646 $ 248

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 29, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 — Income Taxes The Company recorded an income tax provision as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Provision for income taxes $ 1,929 $ 2,315 $ 6,366 $ 6,671 The effective tax rates for the three months ended September 29, 2023 and September 30, 2022 were 28.6 % and 18.4 %, respectively, and were 31.9 % and 16.9 % for the nine months ended September 29, 2023 and September 30, 2022 , respectively. The Company’s effective tax rates differ from the U.S. federal statutory rate of 21 % for the three and nine months ended September 29, 2023 and September 30, 2022 , respectively, primarily due to the income tax expense generated in foreign jurisdictions.

Defined Benefit Pension Plans

Defined Benefit Pension Plans	9 Months Ended
Defined Benefit Pension Plans	Sep. 29, 2023
Retirement Benefits [Abstract]
Defined Benefit Pension Plans	Note 10 – Defined Benefit Pension Plans The Company has defined benefit plans covering employees of its Switzerland and Japan operations. The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Service cost (1) $ 256 $ 306 $ 759 $ 941 Interest cost (2) 91 22 268 63 Expected return on plan assets (2) ( 92 ) ( 125 ) ( 270 ) ( 366 ) Prior service credit (2),(3) ( 45 ) ( 44 ) ( 135 ) ( 135 ) Actuarial loss recognized in current period (2),(3) ( 6 ) 98 ( 19 ) 274 Net periodic pension cost $ 204 $ 257 $ 603 $ 777 (1) Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income. (2) Recognized in other expense, net on the Condensed Consolidated Statements of Income. (3) Amounts reclassified from accumulated other comprehensive income (loss). The Company currently is not required to and does not make contributions to its Japan pension plan. The Company’s contributions to its Swiss pension plan are as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Employer contribution $ 269 $ 230 $ 731 $ 666

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 29, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 11 — Stockholders’ Equity Stock-Based Compensation The cost that has been charged against income for stock-based compensation is set forth below (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Employee stock options $ 3,517 $ 2,865 $ 9,973 $ 7,649 Restricted stock 201 67 347 618 Restricted stock units 2,214 1,249 5,963 3,242 Performance stock units 2,449 1,240 5,958 2,932 Nonemployee stock options 465 306 1,093 934 Total stock-based compensation expense $ 8,846 $ 5,727 $ 23,334 $ 15,375 The Company recorded stock-based compensation costs in the following categories (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Cost of sales $ 223 $ 233 $ 595 $ 409 General and administrative 4,049 2,584 11,107 7,171 Selling and marketing 2,561 1,335 5,910 3,548 Research and development 2,013 1,575 5,722 4,247 Total stock-based compensation expense, net 8,846 5,727 23,334 15,375 Amounts capitalized as part of inventory 534 361 1,431 1,379 Total stock-based compensation expense, gross $ 9,380 $ 6,088 $ 24,765 $ 16,754 Note 11 — Stockholders’ Equity (Continued) Stock-Based Compensation (Continued) As of September 29, 2023, total unrecognized compensation cost related to non-vested stock-based compensation arrangements were as follows (in thousands): September 29, 2023 Stock options $ 23,888 Restricted stock, RSUs and PSUs 24,690 Total unrecognized stock-based compensation cost $ 48,578 The cost is expected to be recognized over a weighted-average period of approximately two years . Incentive Plan The Amended and Restated Omnibus Equity Incentive Plan (“the Plan”) provides for various forms of stock-based incentives. To date, of the available forms of awards under the Plan, the Company has granted only stock options, restricted stock, unrestricted share grants, restricted stock units (“RSUs”) and performance stock units (“PSUs”). Options under the Plan are granted at fair market value on the date of grant, become exercisable generally over a three-year period, or as determined by the Board of Directors, and expire over periods not exceeding 10 years from the date of grant. Certain option and share awards provide for accelerated vesting if there is a change in control and pre-established financial metrics are met (as defined in the Plan). Grants of restricted stock outstanding under the Plan generally vest over periods of one to three years . Grants of RSUs and PSUs outstanding under the Plan generally vest based on service, performance, or a combination of both. On June 15, 2023, stockholders approved a proposal to increase the number of shares under the plan by 2,170,000 shares, for a total of 20,205,000 shares. As of September 29, 2023, there were 2,784,909 shares available for grant under the Plan. Assumptions The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of options granted is derived from the historical exercises and post-vesting cancellations and represents the period of time that options granted are expected to be outstanding. The Company has calculated a 7 % estimated forfeiture rate based on historical forfeiture experience. The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant. Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Expected dividend yield 0 % 0 % 0 % 0 % Expected volatility 60 % 54 % 60 % 54 % Risk-free interest rate 4.18 % 2.91 % 3.91 % 1.88 % Expected term (in years) 5.05 5.10 5.05 5.10 Note 11 — Stockholders’ Equity (Continued) Stock Options A summary of stock option activity under the Plan for nine months ended September 29, 2023 is presented below: Stock Weighted- Weighted- Aggregate Outstanding at December 30, 2022 2,469 $ 39.63 Granted 622 55.84 Exercised ( 500 ) 18.54 Forfeited or expired ( 38 ) 72.49 Outstanding at September 29, 2023 2,553 $ 47.22 6.77 $ 19,641 Exercisable at September 29, 2023 1,663 $ 39.11 5.52 $ 19,641 Restricted Stock, Restricted Stock Units and Performance Stock Units A summary of restricted stock, RSUs and PSUs activity under the Plan for the nine months ended September 29, 2023 is presented below (shares in thousands): Restricted RSUs PSUs Unvested at December 30, 2022 4 192 118 Granted 12 269 182 Vested ( 4 ) ( 94 ) ( 36 ) Forfeited or expired — ( 6 ) ( 13 ) Unvested at September 29, 2023 12 361 251

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 29, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 - Commitments and Contingencies Severance Payable As of September 29, 2023 and December 30, 2022 there was severance payable of $ 422,000 and $ 410,000 , respectively. recognized in other current liabilities on the Consolidated Balance Sheets, which included approximately $ 258,000 and $ 300,000 , respectively, in one-time employee benefits to be paid to certain employees in STAAR Japan who work primarily in IOL sales. During the three and nine months ended September 29, 2023 , the Company recognized $ 80,000 and $ 1,441,000 , respectively, related to this. The Company is expected to incur through the end of 2023, one-time employee benefits of approximately $ 1,457,000 related to this. These one-time employee benefits are recognized in general and administrative expense on the Consolidated Statements of Income. Litigation and Claims From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business. These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability. STAAR maintains insurance coverage for various matters, including product liability and certain securities claims. While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm. Employment Agreements The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective January 1, 2023. He and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Basic and Diluted Net Income Pe

Basic and Diluted Net Income Per Share	9 Months Ended
Basic and Diluted Net Income Per Share	Sep. 29, 2023
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	Note 13 — Basic and Diluted Net Income Per Share The following table sets forth the computation of basic and diluted net income per share (in thousands except per share amounts): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Numerator: Net income $ 4,817 $ 10,262 $ 13,591 $ 32,902 Denominator: Weighted average common shares: Common shares outstanding 48,625 48,106 48,438 47,919 Less: Unvested restricted stock ( 12 ) ( 4 ) ( 12 ) ( 4 ) Denominator for basic calculation 48,613 48,102 48,426 47,915 Weighted average effects of potentially diluted common stock: Stock options 679 1,336 933 1,378 Unvested restricted stock — 2 3 2 RSUs 17 64 67 55 PSUs 61 45 65 21 Denominator for diluted calculation 49,370 49,549 49,494 49,371 Net income per share: Basic $ 0.10 $ 0.21 $ 0.28 $ 0.69 Diluted $ 0.10 $ 0.21 $ 0.27 $ 0.67 The following table sets forth (in thousands) the weighted average number of options to purchase shares of common stock, restricted stock, RSUs and PSUs with either exercise prices or unrecognized compensation cost per share greater than the average market price per share of the Company’s common stock, which were not included in the calculation of diluted per share amounts because the effects would be anti-dilutive. Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Stock options 2,453 864 1,853 865 Restricted stock, RSUs and PSUs 341 2 26 20 Total 2,794 866 1,879 885

Disaggregation of Sales, Geogra

Disaggregation of Sales, Geographic Sales and Product Sales	9 Months Ended
Disaggregation of Sales, Geographic Sales and Product Sales	Sep. 29, 2023
Segment Reporting [Abstract]
Disaggregation of Sales, Geographic Sales and Product Sales	In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data. The following breaks down sales into the following categories (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Non-consignment sales $ 75,296 $ 71,223 $ 230,527 $ 205,236 Consignment sales 5,012 4,823 15,615 15,111 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347 The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10 % of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands): Note 14 — Disaggregation of Sales, Geographic Sales and Product Sales (Continued) Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Domestic $ 4,164 $ 3,873 $ 13,061 $ 10,375 Foreign: China 48,287 42,246 144,716 116,635 Japan 9,175 10,546 28,526 32,481 Other (1) 18,682 19,381 59,839 60,856 Total foreign sales 76,144 72,173 233,081 209,972 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347 (1) No other location individually exceeds 10 % of the total sales. 100 % of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line was as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 ICLs $ 81,069 $ 71,953 $ 244,806 $ 208,550 Other product sales: Cataract IOLs ( 221 ) 2,191 1,295 7,640 Other surgical products (1) ( 540 ) 1,902 41 4,157 Total other product sales ( 761 ) 4,093 1,336 11,797 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347 (1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances. One customer, the Company’s distributor in China, accounted for 60 % and 56 % of net sales for the three months ended September 29, 2023 and September 30, 2022 , respectively, and the same customer accounted for 59 % and 53 % for the nine months ended September 29, 2023 and September 30, 2022, respectively. As of September 29, 2023 and December 30, 2022 , respectively, one customer, the Company’s distributor in China, accounted for 78 % and 59 % of consolidated trade receivables.

COVID-19 Developments

COVID-19 Developments	9 Months Ended
COVID-19 Developments	Sep. 29, 2023
C O V I D19 Developments [Abstract]
COVID-19 Developments	Note 15 — COVID-19 Developments In December 2019, COVID-19 surfaced and in March 2020, the World Health Organization declared a pandemic related to the rapid spread of COVID-19 around the world. The impact of the COVID-19 outbreak on the businesses and the economy in the U.S. and the rest of the world is, and is expected to continue to be, uncertain and may continue to be significant as COVID-19 variant strains emerge. The Company’s revenues have been adversely impacted, and the Company experienced a substantial slowdown in sales beginning March 20, 2020 in global geographies characterized as “hot spots” for the COVID-19 virus, including parts of Europe, North America, Asia, the Middle East and India. In certain of these markets, sales have paused as elective surgeries are discouraged to support COVID-19 related needs. While COVID-19 restrictions have since eased globally, a resurgence of the COVID-19 pandemic in global geographies, depending upon its duration and severity, could material adversely impact the global economy and the Company's industry, operations and financial condition and performance. The Company continues to monitor the commercial and operational impact of new variants of COVID-19 in its markets.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 29, 2023
Accounting Policies [Abstract]
Basis of Presentation	The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of December 30, 2022 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022. The Condensed Consolidated Financial Statements for the three and nine months ended September 29, 2023 and September 30, 2022, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and nine months ended September 29, 2023 and September 30, 2022, are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks. Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.
Revision of Financial Statements for Correction of Immaterial Misstatements	Revision of Financial Statements for Correction of Immaterial Misstatements Subsequent to the issuance of the Company’s consolidated financial statements for the year ended December 30, 2022, the Company determined that it had not correctly deducted compensation expense in calculating its income tax provision, deferred tax asset and valuation allowance under the Incremental Cash Tax Method. This resulted in an understatement of the net deferred tax asset, an overstatement in the valuation allowance, an overstatement of the provision for income taxes and understatement of net income. In accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality, and SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated the error and determined that the related impact was not material to results of operations or financial position for any prior annual or interim period, but that correcting the cumulative impact of the error would be material to our results of operations for the year ended December 29, 2023. Accordingly, the Company has corrected the consolidated balance sheet as of December 30, 2022 and the consolidated statements of income and comprehensive income for the years ended December 30, 2022 and December 31, 2021. The effects of the revision on the previously issued consolidated financial statements were as follows: Condensed Consolidated Balance Sheet (in thousands) (Unaudited) December 30, 2022 As Previously Reported Adjustment As revised Deferred income taxes $ 4,824 $ 3,920 $ 8,744 Total assets 414,898 3,920 418,818 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Total liabilities and stockholders’ equity 414,898 3,920 418,818 Note 1 — Basis of Presentation and Significant Accounting Policies (Continued) Revision of Financial Statements for Correction of Immaterial Misstatements (Continued) Condensed Consolidated Statements of Stockholders’ Equity (in thousands) (Unaudited) As Previously Reported Adjustment As revised At December 31, 2021 Accumulated deficit $ ( 111,390 ) $ 3,010 $ ( 108,380 ) Total stockholders’ equity 258,558 3,010 261,568 At December 30, 2022 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Condensed Consolidated Statements of Income and Comprehensive Income (in thousands, except per share amounts) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Provision (benefit) for income taxes $ 6,797 $ ( 910 ) $ 5,887 $ 6,803 $ ( 3,010 ) $ 3,793 Net income 38,755 910 39,665 24,501 3,010 27,511 Comprehensive income 42,959 910 43,869 25,998 3,010 29,008 Net income per share: Basic $ 0.81 $ 0.02 $ 0.83 $ 0.52 $ 0.06 $ 0.58 Diluted $ 0.78 $ 0.02 $ 0.80 $ 0.50 $ 0.06 $ 0.56 Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Cash flows from operating activities Net income $ 38,755 $ 910 $ 39,665 $ 24,501 $ 3,010 $ 27,511 Deferred income taxes ( 1,344 ) ( 910 ) ( 2,254 ) 1,495 ( 3,010 ) ( 1,515 )
Cloud-Based Software Implementation Costs	Cloud-Based Software Implementation Costs The Company has entered into cloud-based software hosting arrangements for which it incurs implementation costs. Certain costs incurred during the application development stage are capitalized and included within Prepayments, deposits and other current assets or Other assets on the condensed consolidated balance sheet, depending on the short or long-term nature of such costs, in line with the Company's policy on the accounting for prepaid software hosting arrangements. Costs incurred during the preliminary project stage and post-implementation stage are expensed as incurred. Capitalized cloud-based software implementation costs are amortized, beginning on the date the related software or module is ready for its intended use, on a straight-line basis over the remaining term of the hosting arrangement. Amortization is recognized as a component of selling, general, and administrative expenses, in the same line item as the expense for the associated hosting arrangement. As of September 29, 2023 , the Company recognized $ 1,318,000 of net capitalized cloud-based software implementation costs recorded within Other assets on the condensed consolidated balance sheets. There were no capitalized cloud-based software implementation costs recognized at December 30, 2022. As of September 29, 2023 , these assets are not currently placed into service. No amortization of capitalized cloud-based software implementation costs were recognized during the three and nine months ended September 29, 2023 .

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 29, 2023
Accounting Policies [Abstract]
Schedule of Revision of Financial Statements	Condensed Consolidated Balance Sheet (in thousands) (Unaudited) December 30, 2022 As Previously Reported Adjustment As revised Deferred income taxes $ 4,824 $ 3,920 $ 8,744 Total assets 414,898 3,920 418,818 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Total liabilities and stockholders’ equity 414,898 3,920 418,818 Condensed Consolidated Statements of Stockholders’ Equity (in thousands) (Unaudited) As Previously Reported Adjustment As revised At December 31, 2021 Accumulated deficit $ ( 111,390 ) $ 3,010 $ ( 108,380 ) Total stockholders’ equity 258,558 3,010 261,568 At December 30, 2022 Accumulated deficit ( 72,635 ) 3,920 ( 68,715 ) Total stockholders’ equity 332,192 3,920 336,112 Condensed Consolidated Statements of Income and Comprehensive Income (in thousands, except per share amounts) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Provision (benefit) for income taxes $ 6,797 $ ( 910 ) $ 5,887 $ 6,803 $ ( 3,010 ) $ 3,793 Net income 38,755 910 39,665 24,501 3,010 27,511 Comprehensive income 42,959 910 43,869 25,998 3,010 29,008 Net income per share: Basic $ 0.81 $ 0.02 $ 0.83 $ 0.52 $ 0.06 $ 0.58 Diluted $ 0.78 $ 0.02 $ 0.80 $ 0.50 $ 0.06 $ 0.56 Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) December 30, 2022 December 31, 2021 As Previously Reported Adjustment As revised As Previously Reported Adjustment As revised Cash flows from operating activities Net income $ 38,755 $ 910 $ 39,665 $ 24,501 $ 3,010 $ 27,511 Deferred income taxes ( 1,344 ) ( 910 ) ( 2,254 ) 1,495 ( 3,010 ) ( 1,515 )

Investments Available for Sale

Investments Available for Sale (Tables)	9 Months Ended
Investments Available for Sale (Tables)	Sep. 29, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Investments Available for Sale and Related Fair Value Measurement	Investments available for sale (“AFS”) and the related fair value measurement consisted of the following (dollars in thousands): September 29, 2023 Fair Value Measurements Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Level 1 Level 2 Commercial paper $ 17,102 $ 1 $ ( 5 ) $ 17,098 $ — $ 17,098 Certificates of deposit 4,080 1 ( 2 ) 4,079 — 4,079 U.S. Treasury securities 24,828 — ( 188 ) 24,640 24,640 — U.S. agency securities 9,771 — ( 21 ) 9,750 — 9,750 Corporate debt securities 18,812 2 ( 73 ) 18,741 — 18,741 Total investments AFS $ 74,593 $ 4 $ ( 289 ) $ 74,308 $ 24,640 $ 49,668 December 30, 2022 Fair Value Measurements Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Level 1 Level 2 Commercial paper $ 44,054 $ 11 $ ( 62 ) $ 44,003 $ — $ 44,003 Certificates of deposit 17,355 4 ( 75 ) 17,284 — 17,284 U.S. Treasury securities 21,847 3 ( 15 ) 21,835 21,835 — U.S. agency securities 10,688 16 ( 3 ) 10,701 — 10,701 Corporate debt securities 45,522 4 ( 288 ) 45,238 — 45,238 Total investments AFS $ 139,466 $ 38 $ ( 443 ) $ 139,061 $ 21,835 $ 117,226
Summary of Fair Value of Investments Available for Sale by Contractual Maturity	The following table shows the fair value of investments AFS by contractual maturity (dollars in thousands): As of September 29, 2023 Within one year After one year through five years Total Commercial paper $ 17,098 $ — $ 17,098 Certificates of deposit 4,079 — 4,079 U.S. Treasury securities 14,855 9,785 24,640 U.S. agency securities 9,354 396 9,750 Corporate debt securities 15,295 3,446 18,741 Total investments AFS $ 60,681 $ 13,627 $ 74,308

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 29, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands): September 29, 2023 December 30, 2022 Raw materials and purchased parts $ 9,591 $ 6,703 Work in process 6,451 5,499 Finished goods 18,944 13,633 Total inventories, gross 34,986 25,835 Less inventory reserves ( 3,925 ) ( 1,674 ) Total inventories, net $ 31,061 $ 24,161

Prepayments, Deposits, and Ot_2

Prepayments, Deposits, and Other Current Assets (Tables)	9 Months Ended
Prepayments, Deposits, and Other Current Assets (Tables)	Sep. 29, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule Of Prepayments, Deposits, and Other Current Assets	Prepayments, deposits, and other current assets consisted of the following (in thousands): September 29, 2023 December 30, 2022 Prepayments and deposits $ 5,830 $ 3,986 Prepaid insurance 455 2,620 Prepaid marketing costs 4,543 2,534 Consumption tax receivable 777 864 Value added tax (VAT) receivable 2,189 2,661 BVG (Swiss Pension) prepayment 801 111 Other (1) 932 700 Total prepayments, deposits and other current assets $ 15,527 $ 13,476 (1) No individual category in “other current assets” exceeds 5 % of the total prepayments, deposits and other current assets.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
Property, Plant and Equipment (Tables)	Sep. 29, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, plant and equipment, net consisted of the following (in thousands): September 29, 2023 December 30, 2022 Machinery and equipment $ 29,461 $ 28,026 Computer equipment and software 8,329 9,266 Furniture and fixtures 4,110 4,276 Leasehold improvements 10,047 14,965 Construction in process 40,174 32,269 Total property, plant and equipment, gross 92,121 88,802 Less accumulated depreciation ( 29,235 ) ( 37,881 ) Total property, plant and equipment, net $ 62,886 $ 50,921

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Sep. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net consisted of the following (in thousands): September 29, 2023 December 30, 2022 Long-lived amortized intangible assets Gross Accumulated Net Gross Accumulated Net Patents and licenses $ 9,180 $ ( 9,180 ) $ — $ 9,240 $ ( 9,067 ) $ 173

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	9 Months Ended
Other Current Liabilities (Tables)	Sep. 29, 2023
Other Liabilities Disclosure [Abstract]
Schedule of Other Current Liabilities	Other current liabilities consisted of the following (in thousands): September 29, 2023 December 30, 2022 Accrued salaries and wages $ 11,813 $ 10,862 Accrued bonuses 2,517 6,925 Income taxes payable 8,540 3,845 Marketing obligations 1,571 1,374 Other (1) 11,824 7,735 Total other current liabilities $ 36,265 $ 30,741 (1) No individual category in “Other” exceeds 5 % of the other current liabilities.

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 29, 2023
Leases [Abstract]
Supplemental Balance Sheet Information Related to Finance Leases	Supplemental balance sheet information related to finance leases consisted of the following (dollars in thousands): Note 8 – Leases (Continued) Finance Leases (Continued) September 29, 2023 December 30, 2022 Machinery and equipment $ — $ 30 Computer equipment and software 6 18 Furniture and fixtures 475 475 Finance lease right-of-use assets, gross 481 523 Less accumulated depreciation ( 261 ) ( 181 ) Finance lease right-of-use assets, net $ 220 $ 342 Current finance lease obligations $ 164 $ 169 Long-term finance lease obligations 84 210 Total finance lease liability $ 248 $ 379 Weighted-average remaining lease term (in years) 1.5 2.2 Weighted-average discount rate 4.23 % 4.10 %
Supplemental Cash Flow Information Related to Finance Leases	Supplemental cash flow information related to finance leases consisted of the following (dollars in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Amortization of finance lease right-of-use asset $ 37 $ 39 $ 114 $ 121 Interest on finance lease liabilities 3 5 10 13 Cash paid for amounts included in the measurement of finance lease liabilities: Operating cash flows 3 5 10 13 Financing cash flows 39 40 121 85
Supplemental Balance Sheet Information Related to Operating Leases	Supplemental balance sheet information related to operating leases consisted of the following (dollars in thousands): September 29, 2023 December 30, 2022 Machinery and equipment $ 726 $ 789 Computer equipment and software 446 446 Real property 41,313 34,465 Operating lease right-of-use assets, gross 42,485 35,700 Less accumulated depreciation ( 7,493 ) ( 5,430 ) Operating lease right-of-use assets, net $ 34,992 $ 30,270 Current operating lease obligations $ 4,003 $ 3,524 Long-term operating lease obligations 31,643 27,136 Total operating lease liability $ 35,646 $ 30,660 Weighted-average remaining lease term (in years) 7.5 7.5 Weighted-average discount rate 5.15 % 3.87 %
Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases was as follows (dollars in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Operating lease cost $ 1,419 $ 1,167 $ 3,883 $ 3,471 Cash paid for amounts included in the measurement of operating lease liabilities: Operating cash flows 1,259 1,103 3,584 3,069 Right-of-use assets obtained in exchange for new operating lease liabilities 4,580 126 8,000 1,166
Schedule of Estimated Future Maturities of Lease Liabilities under Operating and Finance Leases Having Initial or Remaining Non-Cancelable Lease Terms More Than One Year	Estimated future maturities of lease liabilities under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of September 29, 2023 is as follows (in thousands): . As of September 29, 2023 Operating Leases Finance Leases September 2024 $ 5,957 $ 171 September 2025 5,630 85 September 2026 4,987 — September 2027 5,319 — September 2028 5,381 — Thereafter 18,105 — Total future minimum lease payments $ 45,379 $ 256 Less amounts representing interest ( 9,733 ) ( 8 ) Total lease liability $ 35,646 $ 248

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
Income Taxes (Tables)	Sep. 29, 2023
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision	The Company recorded an income tax provision as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Provision for income taxes $ 1,929 $ 2,315 $ 6,366 $ 6,671

Defined Benefit Pension Plans (

Defined Benefit Pension Plans (Tables)	9 Months Ended
Defined Benefit Pension Plans (Tables)	Sep. 29, 2023
Retirement Benefits [Abstract]
Schedule of Net Benefit Costs	The Company has defined benefit plans covering employees of its Switzerland and Japan operations. The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Service cost (1) $ 256 $ 306 $ 759 $ 941 Interest cost (2) 91 22 268 63 Expected return on plan assets (2) ( 92 ) ( 125 ) ( 270 ) ( 366 ) Prior service credit (2),(3) ( 45 ) ( 44 ) ( 135 ) ( 135 ) Actuarial loss recognized in current period (2),(3) ( 6 ) 98 ( 19 ) 274 Net periodic pension cost $ 204 $ 257 $ 603 $ 777 (1) Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income. (2) Recognized in other expense, net on the Condensed Consolidated Statements of Income. (3) Amounts reclassified from accumulated other comprehensive income (loss).
Schedule of Defined Benefit Plans Disclosures	The Company currently is not required to and does not make contributions to its Japan pension plan. The Company’s contributions to its Swiss pension plan are as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Employer contribution $ 269 $ 230 $ 731 $ 666

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 29, 2023
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost	The cost that has been charged against income for stock-based compensation is set forth below (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Employee stock options $ 3,517 $ 2,865 $ 9,973 $ 7,649 Restricted stock 201 67 347 618 Restricted stock units 2,214 1,249 5,963 3,242 Performance stock units 2,449 1,240 5,958 2,932 Nonemployee stock options 465 306 1,093 934 Total stock-based compensation expense $ 8,846 $ 5,727 $ 23,334 $ 15,375
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The Company recorded stock-based compensation costs in the following categories (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Cost of sales $ 223 $ 233 $ 595 $ 409 General and administrative 4,049 2,584 11,107 7,171 Selling and marketing 2,561 1,335 5,910 3,548 Research and development 2,013 1,575 5,722 4,247 Total stock-based compensation expense, net 8,846 5,727 23,334 15,375 Amounts capitalized as part of inventory 534 361 1,431 1,379 Total stock-based compensation expense, gross $ 9,380 $ 6,088 $ 24,765 $ 16,754
Schedule of Unrecognized Compensation Cost, Non-Vested Stock-Based Compensation Arrangements	As of September 29, 2023, total unrecognized compensation cost related to non-vested stock-based compensation arrangements were as follows (in thousands): September 29, 2023 Stock options $ 23,888 Restricted stock, RSUs and PSUs 24,690 Total unrecognized stock-based compensation cost $ 48,578
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant. Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Expected dividend yield 0 % 0 % 0 % 0 % Expected volatility 60 % 54 % 60 % 54 % Risk-free interest rate 4.18 % 2.91 % 3.91 % 1.88 % Expected term (in years) 5.05 5.10 5.05 5.10
Schedule of Share-based Compensation, Stock Options, Activity	A summary of stock option activity under the Plan for nine months ended September 29, 2023 is presented below: Stock Weighted- Weighted- Aggregate Outstanding at December 30, 2022 2,469 $ 39.63 Granted 622 55.84 Exercised ( 500 ) 18.54 Forfeited or expired ( 38 ) 72.49 Outstanding at September 29, 2023 2,553 $ 47.22 6.77 $ 19,641 Exercisable at September 29, 2023 1,663 $ 39.11 5.52 $ 19,641
Schedule of Share-based Compensation, Restricted Stock, RSUs and PSUs Activity	A summary of restricted stock, RSUs and PSUs activity under the Plan for the nine months ended September 29, 2023 is presented below (shares in thousands): Restricted RSUs PSUs Unvested at December 30, 2022 4 192 118 Granted 12 269 182 Vested ( 4 ) ( 94 ) ( 36 ) Forfeited or expired — ( 6 ) ( 13 ) Unvested at September 29, 2023 12 361 251

Basic and Diluted Net Income _2

Basic and Diluted Net Income Per Share (Tables)	9 Months Ended
Basic and Diluted Net Income Per Share (Tables)	Sep. 29, 2023
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income Per Share	The following table sets forth the computation of basic and diluted net income per share (in thousands except per share amounts): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Numerator: Net income $ 4,817 $ 10,262 $ 13,591 $ 32,902 Denominator: Weighted average common shares: Common shares outstanding 48,625 48,106 48,438 47,919 Less: Unvested restricted stock ( 12 ) ( 4 ) ( 12 ) ( 4 ) Denominator for basic calculation 48,613 48,102 48,426 47,915 Weighted average effects of potentially diluted common stock: Stock options 679 1,336 933 1,378 Unvested restricted stock — 2 3 2 RSUs 17 64 67 55 PSUs 61 45 65 21 Denominator for diluted calculation 49,370 49,549 49,494 49,371 Net income per share: Basic $ 0.10 $ 0.21 $ 0.28 $ 0.69 Diluted $ 0.10 $ 0.21 $ 0.27 $ 0.67
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Stock options 2,453 864 1,853 865 Restricted stock, RSUs and PSUs 341 2 26 20 Total 2,794 866 1,879 885

Disaggregation of Sales, Geog_2

Disaggregation of Sales, Geographic Sales and Product Sales (Tables)	9 Months Ended
	Sep. 29, 2023
Segment Reporting [Abstract]
Disaggregation of Sales	In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data. The following breaks down sales into the following categories (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Non-consignment sales $ 75,296 $ 71,223 $ 230,527 $ 205,236 Consignment sales 5,012 4,823 15,615 15,111 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347
Net Sales by Geographic Areas	The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 Domestic $ 4,164 $ 3,873 $ 13,061 $ 10,375 Foreign: China 48,287 42,246 144,716 116,635 Japan 9,175 10,546 28,526 32,481 Other (1) 18,682 19,381 59,839 60,856 Total foreign sales 76,144 72,173 233,081 209,972 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347 (1) No other location individually exceeds 10 % of the total sales.
Net Sales by Products and Services	The composition of the Company’s net sales by product line was as follows (in thousands): Three Months Ended Nine Months Ended September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022 ICLs $ 81,069 $ 71,953 $ 244,806 $ 208,550 Other product sales: Cataract IOLs ( 221 ) 2,191 1,295 7,640 Other surgical products (1) ( 540 ) 1,902 41 4,157 Total other product sales ( 761 ) 4,093 1,336 11,797 Total net sales $ 80,308 $ 76,046 $ 246,142 $ 220,347 (1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 29, 2023	Sep. 29, 2023	Dec. 30, 2022
Accounting Policies [Abstract]
Capitalized cloud-based software implementation costs	$ 1,318,000	$ 1,318,000	$ 0
Amortization of capitalized cloud-based software implementation costs	$ 0	$ 0

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Schedule of Revision of Financial Statements - Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Jun. 30, 2023	Dec. 30, 2022	Sep. 30, 2022	Jul. 01, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred income taxes	$ 8,560		$ 8,744
Total assets	471,521		418,818
Accumulated deficit	(55,124)		(68,715)			$ (108,380)
Total stockholders' equity	378,595	$ 357,617	336,112	$ 323,142	$ 302,317	261,568
Total liabilities and stockholders' equity	$ 471,521		418,818
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred income taxes			4,824
Total assets			414,898
Accumulated deficit			(72,635)			(111,390)
Total stockholders' equity			332,192			258,558
Total liabilities and stockholders' equity			414,898
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred income taxes			3,920
Total assets			3,920
Accumulated deficit			3,920			3,010
Total stockholders' equity			3,920			$ 3,010
Total liabilities and stockholders' equity			$ 3,920

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Schedule of Revision of Financial Statements - Condensed Consolidated Statements of Stockholders' Equity (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Jun. 30, 2023	Dec. 30, 2022	Sep. 30, 2022	Jul. 01, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit	$ (55,124)		$ (68,715)			$ (108,380)
Total stockholders' equity	$ 378,595	$ 357,617	336,112	$ 323,142	$ 302,317	261,568
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit			(72,635)			(111,390)
Total stockholders' equity			332,192			258,558
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit			3,920			3,010
Total stockholders' equity			$ 3,920			$ 3,010

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Schedule of Revision of Financial Statements - Condensed Consolidated Statements of Income and Comprehensive Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022	Dec. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	$ 1,929	$ 2,315	$ 6,366	$ 6,671	$ 5,887	$ 3,793
Net Income (Loss)	4,817	10,262	13,591	32,902	39,665	27,511
Comprehensive income	$ 4,452	$ 9,703	$ 10,549	$ 36,640	$ 43,869	$ 29,008
Net income per share:
Basic	$ 0.1	$ 0.21	$ 0.28	$ 0.69	$ 0.83	$ 0.58
Diluted	$ 0.1	$ 0.21	$ 0.27	$ 0.67	$ 0.8	$ 0.56
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes					$ 6,797	$ 6,803
Net Income (Loss)					38,755	24,501
Comprehensive income					$ 42,959	$ 25,998
Net income per share:
Basic					$ 0.81	$ 0.52
Diluted					$ 0.78	$ 0.5
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes					$ (910)	$ (3,010)
Net Income (Loss)					910	3,010
Comprehensive income					$ 910	$ 3,010
Net income per share:
Basic					$ 0.02	$ 0.06
Diluted					$ 0.02	$ 0.06

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies - Schedule of Revision of Financial Statements - Condensed Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022	Dec. 30, 2021
Cash flows from operating activities
Net Income (Loss)	$ 4,817	$ 10,262	$ 13,591	$ 32,902	$ 39,665	$ 27,511
Deferred income taxes			$ 65	$ 23	(2,254)	(1,515)
As Previously Reported
Cash flows from operating activities
Net Income (Loss)					38,755	24,501
Deferred income taxes					(1,344)	1,495
Adjustment
Cash flows from operating activities
Net Income (Loss)					910	3,010
Deferred income taxes					$ (910)	$ (3,010)

Investments Available for Sal_2

Investments Available for Sale - Summary of Investments Available for Sale and Related Fair Value Measurement (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 29, 2023	Dec. 30, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 74,593	$ 139,466
Unrealized Gains	4	38
Unrealized Losses	(289)	(443)
Estimated Fair Value	74,308	139,061
Fair Value, Inputs, Level 1
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	24,640	21,835
Fair Value, Inputs, Level 2
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	49,668	117,226
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	17,102	44,054
Unrealized Gains	1	11
Unrealized Losses	(5)	(62)
Estimated Fair Value	17,098	44,003
Commercial Paper \| Fair Value, Inputs, Level 2
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	17,098	44,003
Certificates of Deposit
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,080	17,355
Unrealized Gains	1	4
Unrealized Losses	(2)	(75)
Estimated Fair Value	4,079	17,284
Certificates of Deposit \| Fair Value, Inputs, Level 2
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	4,079	17,284
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	24,828	21,847
Unrealized Gains		3
Unrealized Losses	(188)	(15)
Estimated Fair Value	24,640	21,835
U.S. Treasury Securities \| Fair Value, Inputs, Level 1
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	24,640	21,835
U.S. Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,771	10,688
Unrealized Gains		16
Unrealized Losses	(21)	(3)
Estimated Fair Value	9,750	10,701
U.S. Agency Securities \| Fair Value, Inputs, Level 2
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	9,750	10,701
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	18,812	45,522
Unrealized Gains	2	4
Unrealized Losses	(73)	(288)
Estimated Fair Value	18,741	45,238
Corporate Debt Securities \| Fair Value, Inputs, Level 2
Schedule Of Available For Sale Securities [Line Items]
Fair Value Measurements	$ 18,741	$ 45,238

Investments Available for Sal_3

Investments Available for Sale - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 29, 2023	Sep. 29, 2023
Investments, Debt and Equity Securities [Abstract]
Impairment recognized	$ 0	$ 0
Sale of securities		600,000
Realized gain on debt securities available for sale		$ 2,000

Investments Available for Sal_4

Investments Available for Sale - Summary of Fair Value of Investments Available for Sale by Contractual Maturity (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Schedule Of Available For Sale Securities [Line Items]
Within one year	$ 60,681
After one year through five years	13,627
Total	74,308	$ 139,061
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Within one year	17,098
Total	17,098	44,003
Certificates of Deposit
Schedule Of Available For Sale Securities [Line Items]
Within one year	4,079
Total	4,079	17,284
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Within one year	14,855
After one year through five years	9,785
Total	24,640	21,835
U.S. Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Within one year	9,354
After one year through five years	396
Total	9,750	10,701
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Within one year	15,295
After one year through five years	3,446
Total	$ 18,741	$ 45,238

Inventories - Schedule of Inven

Inventories - Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 9,591	$ 6,703
Work in process	6,451	5,499
Finished goods	18,944	13,633
Total inventories, gross	34,986	25,835
Less inventory reserves	(3,925)	(1,674)
Total inventories, net	$ 31,061	$ 24,161

Prepayments, Deposits, and Ot_3

Prepayments, Deposits, and Other Current Assets - Schedule Of Prepayments, Deposits, and Other Current Assets (Details) - USD ($) $ in Thousands		Sep. 29, 2023	Dec. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepayments and deposits		$ 5,830	$ 3,986
Prepaid insurance		455	2,620
Prepaid marketing costs		4,543	2,534
Consumption tax receivable		777	864
Value added tax (VAT) receivable		2,189	2,661
BVG (Swiss Pension) prepayment		801	111
Other	[1]	932	700
Total prepayments, deposits and other current assets		$ 15,527	$ 13,476

[1] No individual category in “other current assets” exceeds 5 % of the total prepayments, deposits and other current assets.

Prepayments, Deposits, and Ot_4

Prepayments, Deposits, and Other Current Assets - Schedule Of Prepayments, Deposits, and Other Current Assets (Parenthetical) (Details)	Sep. 29, 2023	Dec. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Percent of prepayments deposits and other current assets included in other current assets	5%	5%

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Property, Plant and Equipment [Abstract]
Machinery and equipment	$ 29,461	$ 28,026
Computer equipment and software	8,329	9,266
Furniture and fixtures	4,110	4,276
Leasehold improvements	10,047	14,965
Construction in process	40,174	32,269
Total property, plant and equipment, gross	92,121	88,802
Less accumulated depreciation	(29,235)	(37,881)
Total property, plant and equipment, net	$ 62,886	$ 50,921

Intangible Assets - Schedule of

Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Finite Lived Intangible Assets [Line Items]
Long-lived intangible assets, Net		$ 173
Patents and licenses
Finite Lived Intangible Assets [Line Items]
Long-lived intangible assets, Gross Carrying Amount	$ 9,180	9,240
Long-lived intangible assets, Accumulated Amortization	(9,180)	(9,067)
Long-lived intangible assets, Net	$ 0	$ 173

Intangible Assets - Additional

Intangible Assets - Additional Information (Details)	9 Months Ended
Intangible Assets - Additional Information (Details)	Sep. 29, 2023 USD ($)
Patents and licenses \| Cataract IOLs \| Japan
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 154,000

Other Current Liabilities - Sch

Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands		Sep. 29, 2023	Dec. 30, 2022
Other Liabilities Disclosure [Abstract]
Accrued salaries and wages		$ 11,813	$ 10,862
Accrued bonuses		2,517	6,925
Income taxes payable		8,540	3,845
Marketing obligations		1,571	1,374
Other	[1]	11,824	7,735
Total other current liabilities		$ 36,265	$ 30,741

[1] No individual category in “Other” exceeds 5 % of the other current liabilities.

Other Current Liabilities - S_2

Other Current Liabilities - Schedule of Other Current Liabilities (Parenthetical) (Details)	Sep. 29, 2023	Dec. 30, 2022
Other Liabilities Disclosure [Abstract]
Percent of Other Current Liabilities Included in Other	5%	5%

Leases - Additional Information

Leases - Additional Information (Details)	Sep. 29, 2023
Minimum
Lessee Lease Description [Line Items]
Finance lease, term of contract	2 years
Operating lease, term of contract	2 years
Maximum
Lessee Lease Description [Line Items]
Finance lease, term of contract	5 years
Operating lease, term of contract	10 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Finance Leases (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Lessee Lease Description [Line Items]
Finance lease right-of-use assets, gross	$ 481	$ 523
Less accumulated depreciation	(261)	(181)
Finance lease right-of-use assets, net	220	342
Current finance lease obligations	164	169
Long-term finance lease obligations	84	210
Total finance lease liability	$ 248	$ 379
Weighted-average remaining lease term (in years)	1 year 6 months	2 years 2 months 12 days
Weighted-average discount rate	4.23%	4.10%
Machinery and Equipment
Lessee Lease Description [Line Items]
Finance lease right-of-use assets, gross		$ 30
Computer Equipment and Software
Lessee Lease Description [Line Items]
Finance lease right-of-use assets, gross	$ 6	18
Furniture and Fixtures
Lessee Lease Description [Line Items]
Finance lease right-of-use assets, gross	$ 475	$ 475

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Finance Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Leases [Abstract]
Amortization of finance lease right-of-use asset	$ 37	$ 39	$ 114	$ 121
Interest on finance lease liabilities	3	5	10	13
Cash paid for amounts included in the measurement of finance lease liabilities:
Operating cash flows	3	5	10	13
Financing cash flows	$ 39	$ 40	$ 121	$ 85

Leases - Supplemental Balance_2

Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Lessee Lease Description [Line Items]
Operating lease right-of-use assets, gross	$ 42,485	$ 35,700
Less accumulated depreciation	(7,493)	(5,430)
Operating lease right-of-use assets, net	34,992	30,270
Current operating lease obligations	4,003	3,524
Long-term operating lease obligations	31,643	27,136
Total operating lease liability	$ 35,646	$ 30,660
Weighted-average remaining lease term (in years)	7 years 6 months	7 years 6 months
Weighted-average discount rate	5.15%	3.87%
Machinery and Equipment
Lessee Lease Description [Line Items]
Operating lease right-of-use assets, gross	$ 726	$ 789
Computer Equipment and Software
Lessee Lease Description [Line Items]
Operating lease right-of-use assets, gross	446	446
Real Property
Lessee Lease Description [Line Items]
Operating lease right-of-use assets, gross	$ 41,313	$ 34,465

Leases - Supplemental Cash Fl_2

Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease cost	$ 1,419	$ 1,167	$ 3,883	$ 3,471
Cash paid for amounts included in the measurement of operating lease liabilities:
Operating cash flows	1,259	1,103	3,584	3,069
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 4,580	$ 126	$ 8,000	$ 1,166

Leases - Schedule of Estimated

Leases - Schedule of Estimated Future Maturities of Lease Liabilities under Operating and Finance Leases Having Initial or Remaining Non-Cancelable Lease Terms More Than One Year (Details) - USD ($) $ in Thousands	Sep. 29, 2023	Dec. 30, 2022
Operating Lease Liabilities, Payments, Due, Rolling Maturity [Abstract]
September 2024	$ 5,957
September 2025	5,630
September 2026	4,987
September 2027	5,319
September 2028	5,381
Thereafter	18,105
Total future minimum lease payments	45,379
Less amounts representing interest	(9,733)
Total lease liability	35,646	$ 30,660
Finance Lease Liabilities, Payments, Rolling Maturity [Abstract]
September 2024	171
September 2025	85
Total future minimum lease payments	256
Less amounts representing interest	(8)
Total lease liability	$ 248	$ 379

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022	Dec. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 1,929	$ 2,315	$ 6,366	$ 6,671	$ 5,887	$ 3,793

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Details)	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	28.60%	18.40%	31.90%	16.90%
Effective tax rates differ from U.S. federal statutory rate	21%	21%	21%	21%

Defined Benefit Pension Plans -

Defined Benefit Pension Plans - Schedule of Net Benefit Costs (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Retirement Benefits [Abstract]
Service cost	[1]	$ 256	$ 306	$ 759	$ 941
Interest cost	[2]	91	22	268	63
Expected return on plan assets	[2]	(92)	(125)	(270)	(366)
Prior service credit	[2],[3]	(45)	(44)	(135)	(135)
Actuarial loss recognized in current period	[2],[3]	(6)	98	(19)	274
Net periodic pension cost		$ 204	$ 257	$ 603	$ 777

[1] Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income. Recognized in other expense, net on the Condensed Consolidated Statements of Income. Amounts reclassified from accumulated other comprehensive income (loss).

Defined Benefit Pension Plans_2

Defined Benefit Pension Plans - Schedule of Defined Benefit Plans Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Swiss pension plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contribution	$ 269	$ 230	$ 731	$ 666

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 8,846	$ 5,727	$ 23,334	$ 15,375
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	3,517	2,865	9,973	7,649
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	201	67	347	618
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	2,214	1,249	5,963	3,242
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	2,449	1,240	5,958	2,932
Non Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 465	$ 306	$ 1,093	$ 934

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense, net	$ 8,846	$ 5,727	$ 23,334	$ 15,375
Amounts capitalized as part of inventory	534	361	1,431	1,379
Total stock-based compensation expense, gross	9,380	6,088	24,765	16,754
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense, net	223	233	595	409
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense, net	4,049	2,584	11,107	7,171
Selling and Marketing
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense, net	2,561	1,335	5,910	3,548
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense, net	$ 2,013	$ 1,575	$ 5,722	$ 4,247

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - shares		9 Months Ended
	Jun. 15, 2023	Sep. 29, 2023
Stockholders Equity Note [Line Items]
Weighted-average period of cost expected to recognize		2 years
Estimated forfeiture rate		7%
Omnibus Plan
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award, expiration period		10 years
Share-based compensation arrangement by share-based payment award, number of additional shares authorized	2,170,000
Share-based compensation arrangement by share-based payment award, number of shares authorized	20,205,000
Omnibus Plan \| Employee Stock Option
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award, vesting period		3 years
Omnibus Plan \| Restricted Stock
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant		2,784,909
Omnibus Plan \| Restricted Stock \| Minimum
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award, vesting period		1 year
Omnibus Plan \| Restricted Stock \| Maximum
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award, vesting period		3 years

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Unrecognized Compensation Cost Related to Non-Vested Stock-Based Compensation Arrangements (Details) $ in Thousands	Sep. 29, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Stock options	$ 23,888
Restricted stock, RSUs and PSUs	24,690
Total unrecognized stock-based compensation cost	$ 48,578

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Expected dividend yield	0%	0%	0%	0%
Expected volatility	60%	54%	60%	54%
Risk-free interest rate	4.18%	2.91%	3.91%	1.88%
Expected term (in years)	5 years 18 days	5 years 1 month 6 days	5 years 18 days	5 years 1 month 6 days

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Share-based Compensation, Stock Options, Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 29, 2023
Stockholders' Equity Note [Abstract]
Options, Outstanding at December 30, 2022	2,469
Options, Granted, Shares	622
Options, Exercised, Shares	(500)
Options, Forfeited or expired, Shares	(38)
Options, Outstanding at September 29 , 2023	2,553
Options, Exercisable at September 29, 2023	1,663
Weighted Average Exercise Price, Options Outstanding at December 30, 2022	$ 39.63
Weighted Average Exercise Price, Options, Granted	55.84
Weighted Average Exercise Price,Options, Exercised	18.54
Weighted Average Exercise Price, Options, Forfeited or Expired	72.49
Weighted Average Exercise Price, Options Outstanding at September 29, 2023	47.22
Weighted Average Exercise Price, Options Exercisable at September 29, 2023	$ 39.11
Weighted Average Remaining Contractual Term, Options, Outstanding at September 29, 2023	6 years 9 months 7 days
Weighted Average Remaining Contractual Term, Options, Exercisable at September 29, 2023	5 years 6 months 7 days
Aggregate Intrinsic Value, Options, Outstanding at September 29, 2023	$ 19,641
Aggregate Intrinsic Value, Options, Outstanding at September 29, 2023	$ 19,641

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Share-based Compensation, Restricted Stock, RSUs and PSUs Activity (Details) shares in Thousands	9 Months Ended
	Sep. 29, 2023 shares
Restricted Stock
Schedule of Restricted Stock Restricted Stock Units and Performance Stock Units [Line Items]
Unvested at December 30, 2022	4
Granted	12
Vested	(4)
Unvested at September 29, 2023	12
RSUs
Schedule of Restricted Stock Restricted Stock Units and Performance Stock Units [Line Items]
Unvested at December 30, 2022	192
Granted	269
Vested	(94)
Forfeited or expired	(6)
Unvested at September 29, 2023	361
PSUs
Schedule of Restricted Stock Restricted Stock Units and Performance Stock Units [Line Items]
Unvested at December 30, 2022	118
Granted	182
Vested	(36)
Forfeited or expired	(13)
Unvested at September 29, 2023	251

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 29, 2023	Sep. 29, 2023	Dec. 29, 2023	Dec. 30, 2022
Other Current Liabilities
Loss Contingencies [Line Items]
Severance payable	$ 422,000	$ 422,000		$ 410,000
Severance payable includes one-time employee benefits	258,000	258,000		$ 300,000
General and Administrative
Loss Contingencies [Line Items]
One-time employee termination benefits	$ 80,000	$ 1,441,000
General and Administrative \| Scenario Forecast
Loss Contingencies [Line Items]
One-time employee termination benefits			$ 1,457,000

Basic and Diluted Net Income _3

Basic and Diluted Net Income Per Share - Summary of Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022	Dec. 30, 2022	Dec. 30, 2021
Numerator:
Net Income (Loss)	$ 4,817	$ 10,262	$ 13,591	$ 32,902	$ 39,665	$ 27,511
Weighted average common shares:
Common shares outstanding	48,625	48,106	48,438	47,919
Less: Unvested restricted stock	(12)	(4)	(12)	(4)
Denominator for basic calculation	48,613	48,102	48,426	47,915
Weighted average effects of potentially diluted common stock:
Diluted	49,370	49,549	49,494	49,371
Net income per share:
Basic	$ 0.1	$ 0.21	$ 0.28	$ 0.69	$ 0.83	$ 0.58
Diluted	$ 0.1	$ 0.21	$ 0.27	$ 0.67	$ 0.8	$ 0.56
Employee Stock Option
Weighted average effects of potentially diluted common stock:
Diluted	679	1,336	933	1,378
Unvested Restricted Stock
Weighted average effects of potentially diluted common stock:
Diluted		2	3	2
RSUs
Weighted average effects of potentially diluted common stock:
Diluted	17	64	67	55
PSUs
Weighted average effects of potentially diluted common stock:
Diluted	61	45	65	21

Basic and Diluted Net Income _4

Basic and Diluted Net Income Per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	2,794	866	1,879	885
Employee Stock Option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	2,453	864	1,853	865
Restricted stock, RSUs and PSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	341	2	26	20

Disaggregation of Sales, Geog_3

Disaggregation of Sales, Geographic Sales and Product Sales - Disaggregation of Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Total net sales	$ 80,308	$ 76,046	$ 246,142	$ 220,347
Non Consignment Sales [Member]
Total net sales	75,296	71,223	230,527	205,236
Consignment Sales [Member]
Total net sales	$ 5,012	$ 4,823	$ 15,615	$ 15,111

Disaggregation of Sales, Geog_4

Disaggregation of Sales, Geographic Sales and Product Sales - Additional Information (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2023 Country	Sep. 30, 2022	Sep. 29, 2023 Country Segment	Sep. 30, 2022	Dec. 30, 2022
Geographic and Product Data [Line Items]
Number of countries in which Company operates \| Country	75		75
Number of operating segments \| Segment			1
Sales Revenue, Net \| Geographic Concentration Risk [Member] \| Other than China and Japan [Member] \| Maximum
Geographic and Product Data [Line Items]
Concentration risk, percentage			10%
Sales Revenue, Net \| Geographic Concentration Risk [Member] \| China [Member] \| Customer One [Member]
Geographic and Product Data [Line Items]
Concentration risk, percentage	60%	56%	59%	53%
Sales Revenue, Net \| Product Concentration Risk [Member] \| Ophthalmic Surgical Product [Member]
Geographic and Product Data [Line Items]
Concentration risk, percentage			100%
Accounts Receivable [Member] \| Geographic Concentration Risk [Member] \| China [Member] \| Customer One [Member]
Geographic and Product Data [Line Items]
Concentration risk, percentage			78%		59%

Disaggregation of Sales, Geog_5

Disaggregation of Sales, Geographic Sales and Product Sales - Net Sales by Geographic Areas (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Geographic And Sales [Line Items]
Total net sales		$ 80,308	$ 76,046	$ 246,142	$ 220,347
Geographic Distribution, Domestic [Member]
Geographic And Sales [Line Items]
Total net sales		4,164	3,873	13,061	10,375
Geographic Distribution, Foreign [Member]
Geographic And Sales [Line Items]
Total net sales		76,144	72,173	233,081	209,972
Geographic Distribution, Foreign [Member] \| China [Member]
Geographic And Sales [Line Items]
Total net sales		48,287	42,246	144,716	116,635
Geographic Distribution, Foreign [Member] \| JAPAN
Geographic And Sales [Line Items]
Total net sales		9,175	10,546	28,526	32,481
Geographic Distribution, Foreign [Member] \| Other [Member]
Geographic And Sales [Line Items]
Total net sales	[1]	$ 18,682	$ 19,381	$ 59,839	$ 60,856

[1] No other location individually exceeds 10 % of the total sales.

Disaggregation of Sales, Geog_6

Disaggregation of Sales, Geographic Sales and Product Sales - Net Sales by Products and Services (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 29, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 30, 2022
Product Information [Line Items]
Total other product sales		$ (761)	$ 4,093	$ 1,336	$ 11,797
Total net sales		80,308	76,046	246,142	220,347
ICLs [Member]
Product Information [Line Items]
Revenue from contract with customer, excluding assessed tax		81,069	71,953	244,806	208,550
Cataract IOLs [Member]
Product Information [Line Items]
Total other product sales		221	2,191	1,295	7,640
Other surgical products [Member]
Product Information [Line Items]
Total other product sales	[1]	$ (540)	$ 1,902	$ 41	$ 4,157

[1] Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances.